drugset / Trial / NCT05237206
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies
Timeline
- Start
- 2022-04-28
- Primary completion
- 2024-07-23
- Completion
- 2024-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SUPLEXA | Unknown | — | Intravenous |
Indications
No indication recorded.